Anzeige
Mehr »
Donnerstag, 18.12.2025 - Börsentäglich über 12.000 News
Breaking News: Übernahme von Weltraum-Technologie ins Portfolio?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
17.12.25 | 21:59
0,576 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.12.Plus Therapeutics Inc.: Plus Therapeutics Expands CNSide Assay Platform to State of California13
09.12.Plus Therapeutics adds key personnel to CNSide Diagnostics team1
09.12.Plus Therapeutics Inc.: Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants1
04.12.Plus Therapeutics Inc.: Plus Therapeutics Highlights Three REYOBIQ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting6
01.12.Plus Therapeutics to present breast cancer treatment data at SABCS10
26.11.H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.001
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
26.11.Plus Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating mit Kursziel 2,00 $4
24.11.Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases445HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
20.11.Plus Therapeutics Inc.: Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer4
17.11.Plus Therapeutics receives Nasdaq extension to meet minimum bid price2
17.11.Plus Therapeutics Inc.: Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement205HOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
► Artikel lesen
17.11.PLUS THERAPEUTICS, INC. - 8-K, Current Report1
06.11.Plus Therapeutics Inc.: Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.03
03.11.Plus Therapeutics stock price target lowered to $2 at H.C. Wainwright6
30.10.Plus Therapeutics GAAP EPS of -$0.04 misses by $0.01, revenue of $1.4M misses by $0.1M2
30.10.PLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
30.10.Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights147US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct....
► Artikel lesen
21.10.Plus Therapeutics Inc.: Plus Therapeutics Updates on CNSide Diagnostic Platform Launch2
21.10.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
25.09.Plus Therapeutics Pops on UNH Pact18
Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3